Latest Headlines

Latest Headlines

Merck notches another win in India patent battle over diabetes bestsellers

Everything is coming up roses for Merck in its patent battle with India's Glenmark Pharmaceuticals over copycats of the drugmaker's diabetes meds Januvia and Janumet, as the Delhi High Court barred the generics company from selling cheap knockoff versions of the drugs in the country.

Early Gilenya generics now spell trouble for rival MS drugs

Last week, the U.S. Patent Trial and Appeal Board took a long-term Gilenya patent out of commission, putting the Novartis multiple sclerosis drug in line for early generic competition.

U.K. patient group demands government override Roche's Kadcyla patents

Roche has been facing pricing pushback for its breast cancer drug Kadcyla in the U.K., with the country's cost watchdog nixing the med last year and the Cancer Drugs Fund recently rejecting it from its covered list. Now, patients are voicing their discontent, calling on Britain's health minister to override the company's Kadcyla patents and open the door for lower-priced copies.

UPDATED: Novartis falls short in controversial IPR process as board nixes Gilenya patent

The U.S. Patent and Trademark Office's review board has dealt its first blow to Big Pharma. The appeal panel nixed a patent on Novartis' multiple sclerosis blockbuster Gilenya, handing a win to challenger Torrent Pharmaceuticals--and fellow generics makers Mylan and Apotex, which had filed a separate challenge.

UPDATED: Sorry, Celgene, patent board says. Bass can challenge your IP, and profit, too

Drugmakers that have been attacked by patent challenger Kyle Bass would like nothing more than to see him stopped in his tracks by the U.S. Patent and Trademark Office, a move that would also prevent other investment firms from following in his footsteps. But as the Patent Trial and Appeal Board announced on Friday, it's not going to happen.

Sanofi patent deal lets Lilly roll out a Lantus biosim in U.S. next December

Sanofi has put off one biosimilar threat to Lantus till the end of 2016. In a patent settlement announced on Monday, the French drugmaker and U.S.-based Eli Lilly & Co. agreed to a royalty deal covering Lantus SoloStar, the injectable pen version of Sanofi's basal insulin.

Shire chalks up victory in Vyvanse patent battle

Shire is celebrating a victory as a U.S. Court of Appeals upheld its patents for Vyvanse, shielding the med from generic competition while protecting its bottom line even as its has launched a $30 billion buyout run at Baxalta.

EP Vantage: Legal loopholes, price hikes set up aging meds for billions in 2020

In the land of pharma, off-patent drugs usually translate to lost profits. But things don't always shake out that way, according to a new report from EvaluatePharma, which found that companies with aging blockbusters could be set to collect billion-dollar sales for the meds by 2020.

U.K. judge backs Lyrica generic, scolds Pfizer for 'groundless' threats to docs

Pfizer has not only lost a key patent fight over Lyrica in Britain. It's now under fire for threatening legal action against doctors and pharmacies to enforce that very patent.

Undeterred by PTO setbacks, Bass slaps new challenges on Acorda patents

Hedge-fund manager Kyle Bass may have hit some recent speed bumps in his quest to challenge pharma patents through a U.S. Patent and Trademark Office review system. But he's not giving up.